NovaMedica has signed a partnership agreement with Aptalis Pharma to develop and commercialize three of Aptalis' gastrointestinal products in Russia. The products include Pylera, indicated for the eradication of Helicobacter Pylori in patients with gastric or duodenal ulcer; Lacteol, a product derived from a human strain of Lactobacillus LB for use in patients with diarrhea; and Panzytrat, a formulation of pancreatic enzymes indicated for maldigestion due to exocrine pancreatic insufficiency related to cystic fibrosis, chronic pancreatitis, major pancreatic resection, gastric resection.
NovaMedica will work to complete the requirements for regulatory approval of the products in Russia, and subject to approvals, the Aptalis products will launch in 2014-2015.
“Gastrointestinal diseases are one of the most common and socially significant medical issues in Russia. Creating a strategic partnership with Aptalis will be a key success factor to offer to doctors and patients new treatment opportunities in this essential therapeutic area,” said Fabrice Egros, chief operating officer of NovaMedica. “All of these Aptalis proven therapies have properties that are new to the Russian market. With this new alliance, NovaMedica will gain considerable experience on the market place which is in line with our long-term strategy.”